Skip to content


Pharmacogenomics (PGx) Mental Health Panel

Panel Description

Psychiatric disorders such as depression, anxiety, schizophrenia, bipolar disorder, and others impact 1 in 8 adults. 5.5% of all U.S. adults suffer from mental illness, which is defined as disorders that result in serious functional impairment and interfere substantially with activities of daily living.

This panel includes 24 medications and 7 genes associated with Mental Health. Results from this test may help in predicting treatment efficacy and risk of side effects for drugs used to treat various mental health disorders.

Genes Tested (7)


Important Test Information

Turnaround time: 7-10 days

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

Many drugs for psychiatric disorders are impacted in efficacy as well as risk of side effects by specific variations in known genes. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring, can significantly improve outcomes for patients by reducing the burden of failing multiple medications and optimizing chances of efficacious treatment while reducing risk of side effects.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.

Other Tests to Consider

Pharmacogenomics (PGx) Tacrolimus Test

Pharmacogenomics (PGx) Clopidogrel Test